Moreover, we show that immunotherapies (anti-PD1/PD-L1 therapies), neoadjuvant chemotherapy, radiotherapy, and ERBB therapy can be used, either alone or in combination, to treat BLCA with high PMEPA1 expression. Here, PMEPA1 is linked to bladder transitional cell carcinoma.